Unmodified official OCDS data retained by Tenderline for this procurement process.
Complete current OCDS release JSON
{
"id": "014806-2021",
"tag": [
"tender"
],
"date": "2021-06-29T11:59:52+01:00",
"ocid": "ocds-h6vhtk-02c149",
"buyer": {
"id": "GB-FTS-1022",
"name": "Medicines Discovery Catapult"
},
"tender": {
"id": "DN553327",
"lots": [
{
"id": "1",
"value": {
"amount": 35000,
"currency": "GBP"
},
"status": "active",
"hasOptions": false,
"hasRenewal": false,
"description": "The Catapult Centres are a network of world-leading centres designed to transform the UK’s capability for innovation in specific areas and help drive future economic growth.\n(https://catapult.org.uk/catapult-centres/). Our specific area is medicines discovery.\nPart-funded by Innovate UK, an agency of the UK government, we are an independent not-for-profit company. We bring together industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high-value products.\nMDC is a national facility connecting the UK community to accelerate innovative drug discovery.\nWe provide unique scientific capabilities and act as a gateway to UK resources and expertise, supporting UK SMEs in developing new medicines discovery approaches.\nBy validating new ways of discovering medicines and driving key talent and expertise across the sector, we will support the UK life sciences industry, SMEs and innovators to deliver growth for the UK economy and maintain the UK’s heritage position as a global leader in medicines R&D.\nMDC is currently in year 4 of our first 5-year grant funding agreement, referred to (GFA 1). To support our GFA1 evaluation, we have a logic model outlining our theory of change, and a supporting evaluation methodology framework, which we are in the process of implementing.\nIn parallel to the work we are delivering for GFA 1, Innovate UK has asked that we develop our logic model and evaluation methodology framework to support our next grant funding agreement, GFA 2.\nThe estimated value is between £20,000.00 and £35,000.00.\nLink to ITT documents here: https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545",
"contractPeriod": {
"endDate": "2021-10-31T23:59:59Z"
},
"submissionTerms": {
"variantPolicy": "notAllowed"
}
}
],
"items": [
{
"id": "1",
"relatedLot": "1",
"deliveryAddresses": [
{
"region": "UKD62"
}
]
}
],
"title": "Logic Model and Impact Evaluation Methodology",
"status": "active",
"coveredBy": [
"GPA"
],
"bidOpening": {
"date": "2021-07-09T12:05:00+01:00"
},
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"awardPeriod": {
"startDate": "2021-07-09T12:05:00+01:00"
},
"description": "The Catapult Centres are a network of world-leading centres designed to transform the UK’s capability for innovation in specific areas and help drive future economic growth.\n(https://catapult.org.uk/catapult-centres/). Our specific area is medicines discovery.\nPart-funded by Innovate UK, an agency of the UK government, we are an independent not-for-profit company. We bring together industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high-value products.\nMDC is a national facility connecting the UK community to accelerate innovative drug discovery.\nWe provide unique scientific capabilities and act as a gateway to UK resources and expertise, supporting UK SMEs in developing new medicines discovery approaches.\nBy validating new ways of discovering medicines and driving key talent and expertise across the sector, we will support the UK life sciences industry, SMEs and innovators to deliver growth for the UK economy and maintain the UK’s heritage position as a global leader in medicines R&D.\nMDC is currently in year 4 of our first 5-year grant funding agreement, referred to (GFA 1). To support our GFA1 evaluation, we have a logic model outlining our theory of change, and a supporting evaluation methodology framework, which we are in the process of implementing.\nIn parallel to the work we are delivering for GFA 1, Innovate UK has asked that we develop our logic model and evaluation methodology framework to support our next grant funding agreement, GFA 2.\nThe estimated value is between £20,000.00 and £35,000.00.\nLink to ITT documents here: https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545",
"tenderPeriod": {
"endDate": "2021-07-09T12:00:00+01:00"
},
"hasRecurrence": false,
"classification": {
"id": "79000000",
"scheme": "CPV",
"description": "Business services: law, marketing, consulting, recruitment, printing and security"
},
"submissionTerms": {
"languages": [
"en"
],
"bidValidityPeriod": {
"durationInDays": 90
}
},
"submissionMethod": [
"electronicSubmission"
],
"procurementMethod": "open",
"mainProcurementCategory": "services",
"submissionMethodDetails": "https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545",
"procurementMethodDetails": "Open procedure"
},
"parties": [
{
"id": "GB-FTS-1022",
"name": "Medicines Discovery Catapult",
"roles": [
"buyer",
"reviewBody"
],
"address": {
"region": "UKD62",
"locality": "Cheshire",
"postalCode": "SK10 4TG",
"countryName": "United Kingdom",
"streetAddress": "Block 35, Mereside, Alderley Park"
},
"details": {
"url": "https://md.catapult.org.uk/",
"buyerProfile": "https://md.catapult.org.uk/",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"description": "Research - Drug Discovery / Health"
},
{
"scheme": "COFOG",
"description": "Research - Drug Discovery / Health"
}
]
},
"identifier": {
"legalName": "Medicines Discovery Catapult"
},
"contactPoint": {
"url": "https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545",
"name": "Mr Kieran McGowan",
"email": "Kieran.McGowan@md.catapult.org.uk",
"telephone": "+44 1625708394"
},
"additionalContactPoints": [
{
"email": "kieran.mcgowan@md.catapult.org.uk"
}
]
}
],
"language": "en",
"initiationType": "tender"
}Complete JSON history (1 releases)
29 Jun 2021 · 014806-2021 · tender
{
"id": "014806-2021",
"tag": [
"tender"
],
"date": "2021-06-29T11:59:52+01:00",
"ocid": "ocds-h6vhtk-02c149",
"buyer": {
"id": "GB-FTS-1022",
"name": "Medicines Discovery Catapult"
},
"tender": {
"id": "DN553327",
"lots": [
{
"id": "1",
"value": {
"amount": 35000,
"currency": "GBP"
},
"status": "active",
"hasOptions": false,
"hasRenewal": false,
"description": "The Catapult Centres are a network of world-leading centres designed to transform the UK’s capability for innovation in specific areas and help drive future economic growth.\n(https://catapult.org.uk/catapult-centres/). Our specific area is medicines discovery.\nPart-funded by Innovate UK, an agency of the UK government, we are an independent not-for-profit company. We bring together industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high-value products.\nMDC is a national facility connecting the UK community to accelerate innovative drug discovery.\nWe provide unique scientific capabilities and act as a gateway to UK resources and expertise, supporting UK SMEs in developing new medicines discovery approaches.\nBy validating new ways of discovering medicines and driving key talent and expertise across the sector, we will support the UK life sciences industry, SMEs and innovators to deliver growth for the UK economy and maintain the UK’s heritage position as a global leader in medicines R&D.\nMDC is currently in year 4 of our first 5-year grant funding agreement, referred to (GFA 1). To support our GFA1 evaluation, we have a logic model outlining our theory of change, and a supporting evaluation methodology framework, which we are in the process of implementing.\nIn parallel to the work we are delivering for GFA 1, Innovate UK has asked that we develop our logic model and evaluation methodology framework to support our next grant funding agreement, GFA 2.\nThe estimated value is between £20,000.00 and £35,000.00.\nLink to ITT documents here: https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545",
"contractPeriod": {
"endDate": "2021-10-31T23:59:59Z"
},
"submissionTerms": {
"variantPolicy": "notAllowed"
}
}
],
"items": [
{
"id": "1",
"relatedLot": "1",
"deliveryAddresses": [
{
"region": "UKD62"
}
]
}
],
"title": "Logic Model and Impact Evaluation Methodology",
"status": "active",
"coveredBy": [
"GPA"
],
"bidOpening": {
"date": "2021-07-09T12:05:00+01:00"
},
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"awardPeriod": {
"startDate": "2021-07-09T12:05:00+01:00"
},
"description": "The Catapult Centres are a network of world-leading centres designed to transform the UK’s capability for innovation in specific areas and help drive future economic growth.\n(https://catapult.org.uk/catapult-centres/). Our specific area is medicines discovery.\nPart-funded by Innovate UK, an agency of the UK government, we are an independent not-for-profit company. We bring together industry, academia, charities, technologists, services, finance companies, SMEs and start-ups who together can turn good science into new, high-value products.\nMDC is a national facility connecting the UK community to accelerate innovative drug discovery.\nWe provide unique scientific capabilities and act as a gateway to UK resources and expertise, supporting UK SMEs in developing new medicines discovery approaches.\nBy validating new ways of discovering medicines and driving key talent and expertise across the sector, we will support the UK life sciences industry, SMEs and innovators to deliver growth for the UK economy and maintain the UK’s heritage position as a global leader in medicines R&D.\nMDC is currently in year 4 of our first 5-year grant funding agreement, referred to (GFA 1). To support our GFA1 evaluation, we have a logic model outlining our theory of change, and a supporting evaluation methodology framework, which we are in the process of implementing.\nIn parallel to the work we are delivering for GFA 1, Innovate UK has asked that we develop our logic model and evaluation methodology framework to support our next grant funding agreement, GFA 2.\nThe estimated value is between £20,000.00 and £35,000.00.\nLink to ITT documents here: https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545",
"tenderPeriod": {
"endDate": "2021-07-09T12:00:00+01:00"
},
"hasRecurrence": false,
"classification": {
"id": "79000000",
"scheme": "CPV",
"description": "Business services: law, marketing, consulting, recruitment, printing and security"
},
"submissionTerms": {
"languages": [
"en"
],
"bidValidityPeriod": {
"durationInDays": 90
}
},
"submissionMethod": [
"electronicSubmission"
],
"procurementMethod": "open",
"mainProcurementCategory": "services",
"submissionMethodDetails": "https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545",
"procurementMethodDetails": "Open procedure"
},
"parties": [
{
"id": "GB-FTS-1022",
"name": "Medicines Discovery Catapult",
"roles": [
"buyer",
"reviewBody"
],
"address": {
"region": "UKD62",
"locality": "Cheshire",
"postalCode": "SK10 4TG",
"countryName": "United Kingdom",
"streetAddress": "Block 35, Mereside, Alderley Park"
},
"details": {
"url": "https://md.catapult.org.uk/",
"buyerProfile": "https://md.catapult.org.uk/",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"description": "Research - Drug Discovery / Health"
},
{
"scheme": "COFOG",
"description": "Research - Drug Discovery / Health"
}
]
},
"identifier": {
"legalName": "Medicines Discovery Catapult"
},
"contactPoint": {
"url": "https://procontract.due-north.com/RFx/RFxSummary?rfxId=2fb9a540-c5d8-eb11-810c-005056b64545",
"name": "Mr Kieran McGowan",
"email": "Kieran.McGowan@md.catapult.org.uk",
"telephone": "+44 1625708394"
},
"additionalContactPoints": [
{
"email": "kieran.mcgowan@md.catapult.org.uk"
}
]
}
],
"language": "en",
"initiationType": "tender"
}